Breaking News, Collaborations & Alliances

PTC Therapeutics Acquires Agilis Biotherapeutics

Deal adds GT-AADC, an adeno-associated virus gene therapy that treats Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency

PTC Therapeutics has successfully completed the acquisition of Agilis Biotherapeutics, Inc., a private biotechnology company focused on the advancement of innovative gene therapy programs for rare genetic disorders that affect the central nervous system (CNS).  “We are excited to complete the acquisition and welcome the Agilis employees to PTC,” said Stuart W. Peltz, Ph.D., chief executive officer, PTC Therapeutics, Inc. “We have added a team with exceptional gene therapy ex...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters